Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial-Reference-Cited by-同舟云学术

Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial

Published:2018-03-02 Issue:5 Volume:93 Page:655-663
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Candoni Anna¹^ORCID,Papayannidis Cristina²,Martinelli Giovanni²,Simeone Erica¹,Gottardi Michele³,Iacobucci Ilaria²,Gherlinzoni Filippo³,Visani Giuseppe⁴,Baccarani Michele²,Fanin Renato¹

Affiliation:

1. Division of Hematology and SCT; University of Udine; Udine Italy

2. Institute of Hematology and Oncology L. and A. Seràgnoli, University of Bologna; Bologna Italy

3. Division of Hematology; Hospital of Treviso; Treviso Italy

4. Hematology and SCT Center; San Salvatore Hospital; Pesaro Italy

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25057/fullpdf

Reference52 articles.